The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Open accessAbstract
BACKGROUND: Secukinumab is an anti-interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two phase 3 trials of secukinumab in patients with active ankylosing spondylitis. METHODS: In two double-blind trials, we randomly assigned patients to receive secukinumab or placebo. In MEASURE 1, a total of 371 patients received intravenous secukinumab (10 mg per kilogram of body weight) or matched placebo at weeks 0, 2, and 4, followed by subcutaneous secukinumab (150 mg or 75 mg) or matched placebo every 4 weeks starting at week 8. In MEASURE 2, a total of 219 patients received subcutaneous secukinumab (150 mg or 75 mg) or matched placebo at baseline; at weeks 1, 2, and 3; and every 4 weeks starting at week 4. At week 16, patients in the placebo group were randomly reassigned to subcutaneous secukinumab at a dose of 150 mg or 75 mg. The primary end point was the proportion of patients with at least 20% improvement in Assessment of Spondyloarthritis International Society (ASAS20) response criteria at week 16. RESULTS: In MEASURE 1, the ASAS20 response rates at week 16 were 61%, 60%, and 29% for subcutaneous secukinumab at doses of 150 mg and 75 mg and for placebo, respectively (P<0.001 for both comparisons with placebo); in MEASURE 2, the rates were 61%, 41%, and 28% for subcutaneous secukinumab at doses of 150 mg and 75 mg and for placebo, respectively (P<0.001 for the 150-mg dose and P=0.10 for the 75-mg dose). The significant improvements were sustained through 52 weeks. Infections, including candidiasis, were more common with secukinumab than with placebo during the placebo-controlled period of MEASURE 1. During the entire treatment period, pooled exposure-adjusted incidence rates of grade 3 or 4 neutropenia, candida infections, and Crohn's disease were 0.7, 0.9, and 0.7 cases per 100 patient-years, respectively, in secukinumab-treated patients. CONCLUSIONS: Secukinumab at a subcutaneous dose of 150 mg, with either subcutaneous or intravenous loading, provided significant reductions in the signs and symptoms of ankylosing spondylitis at week 16. Secukinumab at a subcutaneous dose of 75 mg resulted in significant improvement only with a higher intravenous loading dose. (Funded by Novartis Pharma; ClinicalTrials.gov numbers, NCT01358175 and NCT01649375.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evaluation of Diagnostic Criteria for Ankylosing Spondylitis
Linden, S. V. D., Valkenburg, H. A., & Cats, A. (1984) · Arthritis & Rheumatism · doi:10.1002/art.1780270401 · Cited by 5,697
Ware, J. E. (2000) · Spine · doi:10.1097/00007632-200012150-00008 · Cited by 4,455
Garrett, S., Jenkinson, T., Kennedy, L. G., Whitelock, H., Gaisford, P., & Călin, A. (1994) · PubMed · Cited by 3,241
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Braun, J., & Sieper, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60635-7 · Cited by 1,806
Self-citationSieper, J., Rudwaleit, M., Baraliakos, X., Brandt, J., Braun, J., Burgos-Vargas, R., Dougados, M., Hermann, K.-G., Landewé, R., Maksymowych, W., et al. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.104018 · Cited by 1,652
Self-citationIL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells
Sherlock, J. P., Joyce-Shaikh, B., Turner, S. P., Chao, C.-C., Sathe, M., Grein, J., Gorman, D. M., Bowman, E. P., McClanahan, T. K., Yearley, J. H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2817 · Cited by 1,060
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
Braun, J., van den Berg, R., Baraliakos, X., Boehm, H., Burgos-Vargas, R., Collantes-Estevez, E., Dagfinrud, H., Dijkmans, B., Dougados, M., Emery, P., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2011.151027 · Cited by 987
Self-citationvan der Heijde, D., Kivitz, A., Schiff, M. H., Sieper, J., Dijkmans, B. A. C., Braun, J., Dougados, M., Reveille, J. D., Wong, R. L., Kupper, H., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21913 · Cited by 872
Self-citationvan der Heijde, D., Dijkmans, B., Geusens, P., Sieper, J., DeWoody, K., Williamson, P., & Braun, J. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20852 · Cited by 860
Self-citation
Cited by
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
van der Heijde, D., Ramiro, S., Landewé, R., Baraliakos, X., Van den Bosch, F., Sepriano, A., Regel, A., Ciurea, A., Dagfinrud, H., Dougados, M., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210770 · Cited by 1,568
Self-citationThe IL-17 Family of Cytokines in Health and Disease
McGeachy, M. J., Cua, D. J., & Gaffen, S. L. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.021 · Cited by 1,443
Sieper, J., & Poddubnyy, D. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31591-4 · Cited by 1,333
Self-citationAnkylosing Spondylitis and Axial Spondyloarthritis
Taurog, J. D., Chhabra, A., & Colbert, R. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1406182 · Cited by 900
Rogler, G., Singh, A., Kavanaugh, A., & Rubin, D. T. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.042 · Cited by 869
Ward, M. M., Deodhar, A., Gensler, L. S., Dubreuil, M., Yu, D., Khan, M. A., Haroon, N., Borenstein, D., Wang, R., Biehl, A., et al. (2019) · Arthritis Care & Research · doi:10.1002/acr.24025 · Cited by 693
Self-citationTherapeutics targeting the IL-23 and IL-17 pathway in psoriasis
Ghoreschi, K., Balato, A., Enerbäck, C., & Sabat, R. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00184-7 · Cited by 668
Ward, M. M., Deodhar, A., Gensler, L. S., Dubreuil, M., Yu, D., Khan, M. A., Haroon, N., Borenstein, D., Wang, R., Biehl, A., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41042 · Cited by 623
Self-citationAnkylosing spondylitis: etiology, pathogenesis, and treatments
Zhu, W., He, X., Cheng, K., Zhang, L., Chen, D., Wang, X., Qiu, G., Cao, X., & Weng, X. (2019) · Bone Research · doi:10.1038/s41413-019-0057-8 · Cited by 502
Interleukin 17 is a chief orchestrator of immunity
Veldhoen, M. (2017) · Nature Immunology · doi:10.1038/ni.3742 · Cited by 475
Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition
Scher, J. U., Ogdie, A., Merola, J. F., & Ritchlin, C. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0175-0 · Cited by 394
Baeten, D., Østergaard, M., Wei, J. C.-C., Sieper, J., Järvinen, P., Tam, L.-S., Salvarani, C., Kim, T.-H., Solinger, A., Datsenko, Y., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213328 · Cited by 390
Self-citationvan der Heijde, D., Deodhar, A., Wei, J. C., Drescher, E., Fleishaker, D., Hendrikx, T., Li, D., Menon, S., & Kanik, K. S. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210322 · Cited by 376
Self-citationvan der Heijde, D., Cheng-Chung Wei, J., Dougados, M., Mease, P., Deodhar, A., Maksymowych, W. P., Van den Bosch, F., Sieper, J., Tomita, T., Landewé, R., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31946-9 · Cited by 370
Self-citationRole of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview
Schinocca, C., Rizzo, C., Fasano, S., Grasso, G., La Barbera, L., Ciccia, F., & Guggino, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.637829 · Cited by 360
Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs
Schett, G., McInnes, I. B., & Neurath, M. F. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1909094 · Cited by 355
Navarro-Compán, V., Sepriano, A., El-Zorkany, B., & van der Heijde, D. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221035 · Cited by 340
Monin, L., & Gaffen, S. L. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028522 · Cited by 339
Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy
Rayego-Mateos, S., Morgado-Pascual, J. L., Opazo-Ríos, L., Guerrero-Hue, M., García-Caballero, C., Vázquez-Carballo, C., Mas, S., Sanz, A. B., Herencia, C., Mezzano, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113798 · Cited by 334
Blauvelt, A., Reich, K., Tsai, T.-F., Tyring, S., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Vender, R., Hugot, S., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.08.008 · Cited by 312
Venken, K., Jacques, P., Mortier, C., Labadia, M. E., Decruy, T., Coudenys, J., Hoyt, K., Wayne, A. L., Hughes, R., Turner, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07911-6 · Cited by 312
Deodhar, A., Mease, P. J., McInnes, I. B., Baraliakos, X., Reich, K., Blauvelt, A., Leonardi, C., Porter, B., Das Gupta, A., Widmer, A., et al. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1882-2 · Cited by 292
Self-citationTH17 cell heterogeneity and its role in tissue inflammation
Schnell, A., Littman, D. R., & Kuchroo, V. K. (2023) · Nature Immunology · doi:10.1038/s41590-022-01387-9 · Cited by 286
Braun, J., Baraliakos, X., Deodhar, A., Baeten, D., Sieper, J., Emery, P., Readie, A., Martin, R., Mpofu, S., & Richards, H. B. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209730 · Cited by 273
Self-citationTh17 plasticity and its relevance to inflammatory bowel disease
Ueno, A., Jeffery, L., Kobayashi, T., Hibi, T., Ghosh, S., & Jijon, H. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2017.12.004 · Cited by 266
Paradoxical gastrointestinal effects of interleukin-17 blockers
Fauny, M., Moulin, D., D'Amico, F., Netter, P., Petitpain, N., Arnone, D., Jouzeau, J.-Y., Loeuille, D., & Peyrin-Biroulet, L. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217927 · Cited by 261
Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.
Fasching, P., Stradner, M., Graninger, W., Dejaco, C., & Fessler, J. (2017) · Molecules · doi:10.3390/molecules22010134 · Cited by 254
McGonagle, D. G., McInnes, I. B., Kirkham, B. W., Sherlock, J., & Moots, R. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215356 · Cited by 254
Biologics for targeting inflammatory cytokines, clinical uses, and limitations
Rider, P., Carmi, Y., & Cohen, I. (2016) · International Journal of Cell Biology · doi:10.1155/2016/9259646 · Cited by 226
Matusiak, Ł., Szczęch, J., Bieniek, A., Nowicka-Suszko, D., & Szepietowski, J. C. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.10.042 · Cited by 185
Beyond Randomized Clinical Trials: Use of External Controls
Schmidli, H., Häring, D. A., Thomas, M., Cassidy, A., Weber, S., & Bretz, F. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1723 · Cited by 125
Targeting interleukin-17 in chronic inflammatory disease: A clinical perspective
Zwicky, P., Unger, S., & Becher, B. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191123 · Cited by 91
MCPIP1/Regnase-1 Restricts IL-17A- and IL-17C-Dependent Skin Inflammation
Monin, L., Gudjonsson, J. E., Childs, E. E., Amatya, N., Xing, X., Verma, A. H., Coleman, B. M., Garg, A. V., Killeen, M., Mathers, A., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601551 · Cited by 82
Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis
Schmidt, T., Schwinge, D., Rolvien, T., Jeschke, A., Schmidt, C., Neven, M., Butscheidt, S., Kriz, M., Kunzmann, L., Mussawy, H., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.12.035 · Cited by 42
Metadata
- Authors
- Baeten, D., Sieper, J., Braun, J., Baraliakos, X., Dougados, M., Emery, P., Deodhar, A., Porter, B., Martin, R., Andersson, M., Mpofu, S., & Richards, H. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-12-24
- Volume
- 373
- Issue
- 26
- Pages
- 2534-2548
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2278932593
- Cited by
- 1,029
- References
- 33
- FWCI
- 70.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.